Nov. 5-7, 2022, Youngene Therapeutics attends the 2022 American Heart Association Conference (AHA 2022) in Chicago, USA.

During the conference, the company held a special discussions on the clinical development strategy of YG1699 heart failure with world-renowned cardiologists. The participating experts and scholars spoke highly on the clinical and pre-clinical study plans and data of YG1699, and were impressed by the SGLT1 inhibitory activity and human pharmacokinetic advantages of YG1699 in human clinical studies. Compared with dapagliflozin head-to-head clinical data, the advantages are significant. Possessing the characteristics and advantages of a new generation of SGLT products, it is expected to carry best-in-class potential for heart failure and diabetes. At the same time, the experts also provided professional guidance and suggestions on the next clinical development strategy and clinical trial plan of YG1699. Several experts expressed their hope to personally participate in the clinical development of YG1699 for heart failure.

YG1699 is a new generation of SGLT1 and SGLT2 dual-inhibitor developed by Youngene, which is currently in phase 2 clinical trials. The data of the clinical IIa study just completed in the United States shows that YG1699 can effectively control postprandial blood sugar and increase endogenous GLP-1 levels. The effect is significantly improved compared to dapagliflozin. As of current, Youngene has had held clinical discussions with the US FDA on heart failure.

About Youngene Therapeutics:

Youngene Therapeutics is a clinical stage biopharmaceutical company. Lead asset YG1699 has completed Phase I and Phase II clinical studies in the US, as well as ethnic bridging studies in China.